Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
CUDC-907 Dual PI3K/HDAC Workflow Guide
2026-09-22
CUDC-907 (SKU A4097) provides a controlled in vitro approach for examining coordinated PI3K and HDAC pathway modulation, including phosphoprotein changes, histone acetylation, cell-cycle behavior, and apoptosis. This guide is based on the product dossier and workflow practice rather than a directly matched paper, and the compound is intended only for scientific research, not diagnostic, therapeutic, or clinical use.
-
HOXC8, Caspase-1, and Pyroptosis in Lung Cancer
2026-09-21
A 2025 Cell Death and Disease study identifies HOXC8 as a transcriptional suppressor of caspase-1 in non-small cell lung carcinoma. Its depletion increases CASP1 abundance and triggers ASC-independent, GSDMD-dependent pyroptosis, revealing an epigenetic mechanism that may help explain how HOXC8 supports lung tumorigenesis.
-
Repaglinide for Metabolic Stress and DNA Repair
2026-09-21
Repaglinide can serve as a reversible metabolic perturbation in experiments probing the energy–DNA repair connection in acute myeloid leukemia. This workflow combines dose and timing controls with ATG4B localization, PRMT1–MRE11 signaling, DNA damage, and viability readouts while clearly separating exploratory use from validated mechanism.
-
LY2886721: Tuning BACE1 Inhibition for Translation
2026-09-20
LY2886721 offers a mechanistically precise way to investigate BACE1-dependent amyloid precursor protein processing, connect amyloid beta reduction with CSF biomarkers, and define exposure levels that preserve synaptic function. This thought-leadership guide translates its cellular and animal evidence into a practical workflow for Alzheimer’s disease researchers.
-
Actinomycin D for RNA Stability in TNBC
2026-09-19
Actinomycin D can convert transcriptional inhibition into a rigorous test of mRNA stability in triple-negative breast cancer models. This article connects ActD assay design with RBMS1–B4GALT1–PD-L1 biology while defining controls that prevent transcriptional stress from being mistaken for immune-regulatory mechanism.
-
NU7441 (KU-57788) DNA-PK Inhibitor Guide
2026-09-18
NU7441, also called KU-57788, is an ATP-competitive DNA-PK inhibitor used in DNA repair research and oncology research. Its reported biochemical selectivity, DMSO solubility, and example cell and xenograft workflows support controlled studies of DNA damage response signaling.
-
BEND Lipids Improve mRNA Delivery and Gene Editing
2026-09-18
The reference study introduces branched endosomal disruptor (BEND) ionizable lipids as a platform for improving lipid nanoparticle delivery of mRNA and CRISPR-Cas9 ribonucleoproteins. Its complementary delivery, editing, and mechanistic experiments connect terminal lipid branching with enhanced endosomal penetration, hepatic gene editing, and T-cell transfection.
-
Iptacopan: From Factor B Mechanism to Translation
2026-09-17
A translational framework for using Iptacopan (LNP023) to connect selective factor B inhibition with quantitative complement assays, disease models, clinical biomarkers, and evidence-based development strategy.
-
BHQ: From SERCA Biology to HSC Mobilization
2026-09-17
A translational perspective on how 2,5-di-tert-butylbenzene-1,4-diol (BHQ) connects SERCA inhibition, calcium homeostasis disruption, ER stress, and hematopoietic stem cell mobilization—while defining the controls needed to move from mechanistic observation to robust research strategy.
-
Iptacopan (LNP023) Complement Research Workflows
2026-09-16
Build more informative complement experiments with a selective, reversible factor B inhibitor that connects enzyme-level potency to serum C3bBb activity, hemolysis, and disease-model endpoints. This workflow-oriented guide covers assay design, translational use cases, and troubleshooting for Iptacopan (LNP023).
-
Polyphyllin H Reverses Paclitaxel Resistance
2026-09-16
The reference study identifies membrane cholesterol and lipid rafts as a shared regulatory environment for ABCB1 and ABCC3 in paclitaxel-resistant breast cancer. Its findings suggest that Polyphyllin H can restore paclitaxel accumulation and antitumor activity through multi-transporter, cholesterol-directed resistance reversal rather than single-transporter inhibition.
-
DHEA at the Ovarian–Neural Translation Interface
2026-09-15
Dehydroepiandrosterone (DHEA) is more than a steroidal reagent: it is a strategically useful perturbation tool for connecting ovarian steroidogenesis, mitochondrial regulation, apoptosis inhibition, and neuroprotection while maintaining clear boundaries between disease modeling and therapeutic interpretation.
-
TRIM26–NDP52 Autophagy Enables PRV Infection
2026-09-15
The reference study identifies TRIM26 as a proviral host factor that promotes pseudorabies virus replication by directing MAVS toward NDP52-mediated selective autophagy. Its gain-of-function, loss-of-function, interaction, and inhibitor experiments connect TRIM26 induction with suppression of RIG-I-dependent type I interferon signaling, providing a mechanistic link between viral immune evasion and autophagic degradation.
-
PPT1–GAP43 Depalmitoylation in Neural Circuits
2026-09-14
Tong et al. identify PPT1 as a functional depalmitoylase for GAP43 at Cys3 and Cys4, linking reversible lipid modification to neuronal morphology, synaptic transmission, and cognitive function. The study combines genetic, biochemical, structural, electrophysiological, and behavioral approaches to show that disrupted PPT1–GAP43 regulation produces circuit hyperexcitability independently of overt lysosomal storage pathology.
-
CGP 55845 Hydrochloride in GABAB Assays
2026-09-14
CGP 55845 hydrochloride is a high-affinity GABAB receptor antagonist for separating receptor-driven neurotransmitter release modulation from astrocytic GAT-3 signaling. This article presents an assay-design framework for interpreting synaptic transmission research and in vitro neurotransmission assays without over-attributing transporter effects to receptor blockade.